In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Sucampo Group

Latest From Sucampo Group

Getting Things Moving: Opportunities In Opioid-Induced Constipation

With relatively few new drugs in development for opioid-induced constipation, the category is wide open for new entrants to conduct clinical studies and make a difference for patients; a Market Spotlight report from Datamonitor Healthcare reviews the indication's outlook.

Gastrointestinal Research & Development

Takeda's Global Ambition

Takeda Pharmaceutical's drug business started out manufacturing and selling bismuth-the basic ingredient in Pepto-Bismol--in 1895. A century later, it's still chained to the stomach-settling game with Prevacid, a $1.4 billion drug whose patent will expire in 2009, taking with it a huge percentage of Takeda's earnings. That's one big reason why Japan's largest and most international pharmaceutical company is on a US-focused dealmaking tear. Since February, Takeda has inked three major licensing partnerships and completed the largest acquisition in its history in a desperate attempt to shore up a thin pipeline.

Pharmaceutical/Biotechnology Deal Statistics Quarterly, Q3 2007

In this issue, we present another installment of our quarterly review of pharmaceutical/biotechnology dealmaking-for July-September 2007. Our data come from Windhover's Strategic Transactions Database.
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Therapeutic Areas
  • Non-Specific
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • Asia
      • Pacific Rim
        • Japan
  • Parent & Subsidiaries
  • Sucampo Group
  • Senior Management
  • Ryuji Ueno, MD, PhD, CEO & CSO
    Ronald W Kaiser, CFO
    Sachiko Kuno, PhD, Chmn. & Pres.
    Kei S Tolliver, VP, Bus. Dev. & Co. Operations
    Gayle Robert Dolecek, SVP, R&D
    Stanley G Miele, SVP, Sales & Mktg.
  • Contact Info
  • Sucampo Group
    Phone: (81) 79-560-7181
    4-1 Techno Park
    Sanda, 669-1339